ArticleNanomedicine (London, England)2013
Ferumoxytol: a new, clinically applicable label for stem-cell tracking in arthritic joints with MRI.
Article in Nanomedicine (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 88 citations in OpenAlex.
- Can the biomolecular corona induce an allergic reaction?-A proof-of-concept study.Biointerphases · 2021Trial
- Beyond radiotheranostics: how imaging modality defines theranostics.European radiology experimental · 2026Review
- Advances in nanotechnology for the diagnosis and management of autoimmune diseases.Asian journal of pharmaceutical sciences · 2026Review
- Receptor-Mediated SPION Labeling of CD4Nanomaterials (Basel, Switzerland) · 2025Article
- Macrophage tracking with USPIO imaging and T2 mapping predicts immune rejection of transplanted stem cells.Scientific reports · 2024Article
- Detection of iron oxide nanoparticle (IONP)-labeled stem cells using quantitative ultrashort echo time imaging: a feasibility study.Quantitative imaging in medicine and surgery · 2023Article
- MegaPro, a clinically translatable nanoparticle forTheranostics · 2023Article
- Polyelectrolyte Coating of Ferumoxytol Differentially Impacts the Labeling of Inflammatory and Steady-State Dendritic Cell Subtypes.Biomedicines · 2022Article
- Cell sorting microbeads as novel contrast agent for magnetic resonance imaging.Scientific reports · 2022Article
- Engineered Protein-Iron Oxide Hybrid Biomaterial for MRI-traceable Drug Encapsulation.Molecular systems design & engineering · 2022Article
- Human integrin α10β1-selected mesenchymal stem cells home to cartilage defects in the rabbit knee and assume a chondrocyte-like phenotype.Stem cell research & therapy · 2022Article
- In vivo imaging of nanoparticle-labeled CAR T cells.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- How to stop using gadolinium chelates for magnetic resonance imaging: clinical-translational experiences with ferumoxytol.Pediatric radiology · 2022Review
- Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle.Theranostics · 2022Review
- Options for imaging cellular therapeutics in vivo: a multi-stakeholder perspective.Cytotherapy · 2021Review
- Ascorbic Acid and Iron Supplement Treatment Improves Stem Cell-Mediated Cartilage Regeneration in a Minipig Model.The American journal of sports medicine · 2021Article
- Personalized-induced neural stem cell therapy: Generation, transplant, and safety in a large animal model.Bioengineering & translational medicine · 2021Article
- Multimodal imaging of hair follicle bulge-derived stem cells in a mouse model of traumatic brain injury.Cell and tissue research · 2020Article
- Comparison of ferumoxytol- and gadolinium chelate-enhanced MRI for assessment of sarcomas in children and adolescents.European radiology · 2020Article
- MRI-Tracking of Dental Pulp Stem Cells In Vitro and In Vivo Using Dextran-Coated Superparamagnetic Iron Oxide Nanoparticles.Journal of clinical medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
Abstract
aimTo develop a clinically applicable MRI technique for tracking stem cells in matrix-associated stem-cell implants, using the US FDA-approved iron supplement ferumoxytol. MATERIALS &
methodsFerumoxytol-labeling of adipose-derived stem cells (ADSCs) was optimized in vitro. A total of 11 rats with osteochondral defects of both femurs were implanted with ferumoxytol- or ferumoxides-labeled or unlabeled ADSCs, and underwent MRI up to 4 weeks post matrix-associated stem-cell implant. The signal-to-noise ratio of different matrix-associated stem-cell implant was compared with t-tests and correlated with histopathology.
resultsAn incubation concentration of 500 µg iron/ml ferumoxytol and 10 µg/ml protamine sulfate led to significant cellular iron uptake, T2 signal effects and unimpaired ADSC viability. In vivo, ferumoxytol- and ferumoxides-labeled ADSCs demonstrated significantly lower signal-to-noise ratio values compared with unlabeled controls (p < 0.01). Histopathology confirmed engraftment of labeled ADSCs, with slow dilution of the iron label over time.
conclusionFerumoxytol can be used for in vivo tracking of stem cells with MRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.